IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Executive Summary
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
You may also be interested in...
France's Dynacure Gets VC Backing To Progress Antisense Candidate For Myopathy
Clinical trials are expected to start next year with an antisense clinical candidate for the rare disease, centronuclear myopathy, developed by French start-up Dynacure as part of its collaboration with US antisense specialist Ionis Pharmaceuticals.
Finance Watch: J&J Notes JLabs Incubators' Success Stories To Date
Private Company Edition: Life science firms in J&J's JLabs incubators have raised $9.4bn to date from deals and financings, including five IPOs. Also, October brings a wide range of new equity and VC financings.
IPO Update: Protagonist, Gemphire, Kadmon Launches Fall Flat
The three most recent biopharma IPOs are trading at or below their offering prices, but the average return for the 22 drug development firms that have gone public so far this year is holding steady at 11% -- thanks to a pair of super performers that have delivered triple-digit returns.